FDA seeks to streamline inactive ingredient database with industry input

The US Food and Drug Administration (FDA) wants to know how it should prioritize maximum daily exposure (MDE) information and whether it should remove dosage form information from its inactive ingredient database (IID). The move is part of the agency’s commitment to industry to streamline the drug database.